title: 5-Aza-2'-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer. Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group.
authors.affiliation: Centre Léon Bérard, Lyon, France.
authors.forename: M
authors.initials: M
authors.lastname: Clavel
authors.forename: S
authors.initials: S
authors.lastname: Monfardini
authors.forename: S
authors.initials: S
authors.lastname: Fosså
authors.forename: J
authors.initials: J
authors.lastname: Smyth
authors.forename: J
authors.initials: J
authors.lastname: Renard
authors.forename: S B
authors.initials: SB
authors.lastname: Kaye
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001374:Azacitidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077209:Decitabine; D004341:Drug Evaluation; D004407:Dysgerminoma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013736:Testicular Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D000077209:Decitabine; D001374:Azacitidine